Patents by Inventor Johannes Spleiss

Johannes Spleiss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TOPICAL TREATMENT OF IMMUNE CHECKPOINT INHIBITOR INDUCED DIARRHOEA, COLITIS OR ENTEROCOLITIS USING ANTIBODIES AND FRAGMENTS THEREOF
    Publication number: 20220119515
    Abstract: The present invention relates to the therapeutic topical use of compositions containing antibody molecules or functional fragments or derivatives specific to tumour necrosis factor alpha (TNF?), for treating or preventing immune checkpoint (ICP) inhibitor-induced adverse events.
    Type: Application
    Filed: December 6, 2019
    Publication date: April 21, 2022
    Applicant: Tillotts Pharma AG
    Inventors: Esther Maria FURRER, Felipe VARUM, Roberto BRAVO, Johannes SPLEISS, Marijana NEDELJKOVIC POTIC, Ortrud GERSTNER, Cristina BRUNO
  • Soft gelatin encapsulated pharmaceutical composition of cis-5,8,11,14,17-eicosapentaenoic acid in free acid form and cis-7,10,13,16,19-docosapentaenoic acid in free acid form
    Patent number: 10314789
    Abstract: Shelf life of soft gelatin capsules comprising a soft gelatin shell encapsulating a pharmaceutical formulation comprising cis-5,8,11,14,17-eicosapentaenoic acid (C20:5 n-3; “EPA”) in free acid form in an amount from 25 wt % to 99 wt % of the formulation and cis-7,10,13,16,19-docosapentaenoic acid (C22:5 n-3; “DPA”) in free acid form in an amount from 1 wt % to 75 wt % of the formulation in which the gelatin component of the shell is Type B gelatin, is improved by replacing up to 75 wt % of the gelatin component with porcine Type A gelatin.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: June 11, 2019
    Assignee: Chrysalis Pharma AG
    Inventor: Johannes Spleiss
  • SOFT GELATIN ENCAPSULATED PHARMACEUTICAL COMPOSITION OF CIS-5,8,11,14,17-EICOSAPENTAENOIC ACID IN FREE ACID FORM AND CIS-7,10,13,16,19-DOCOSAPENTAENOIC ACID IN FREE ACID FORM
    Publication number: 20190167599
    Abstract: Shelf life of soft gelatin capsules comprising a soft gelatin shell encapsulating a pharmaceutical formulation comprising cis-5,8,11,14,17-eicosapentaenoic acid (C20:5 n-3; “EPA”) in free acid form in an amount from 25 wt % to 99 wt % of the formulation and cis-7,10,13,16,19-docosapentaenoic acid (C22:5 n-3; “DPA”) in free acid form in an amount from 1 wt % to 75 wt % of the formulation in which the gelatin component of the shell is Type B gelatin, is improved by replacing up to 75 wt % of the gelatin component with porcine Type A gelatin.
    Type: Application
    Filed: January 24, 2019
    Publication date: June 6, 2019
    Applicant: Chrysalis Pharma AG
    Inventor: Johannes SPLEISS
  • PHARMACEUTICAL COMPOSITION
    Publication number: 20150297529
    Abstract: Shelf life of soft gelatin capsules comprising a soft gelatin shell encapsulating a pharmaceutical formulation comprising cis-5,8,11,14,17-eicosapentaenoic acid (C20:5 n-3; “EPA”) in free acid form in an amount from 25 wt % to 99 wt % of the formulation and cis-7,10,13,16,19-docosapentaenoic acid (C22:5 n-3; “DPA”) in free acid form in an amount from 1 wt % to 75 wt % of the formulation in which the gelatin component of the shell is Type B gelatin, is improved by replacing up to 75 wt % of the gelatin component with porcine Type A gelatin.
    Type: Application
    Filed: September 6, 2013
    Publication date: October 22, 2015
    Applicant: CHRYSALIS PHARMA AG
    Inventor: Johannes Spleiss